Summary
The U.S. and U.K. have reached a trade deal that will exempt drugs imported from the U.K. from tariffs for three years in exchange for pricing concessions. This agreement aims to balance drug costs between the two countries and encourage investment in the U.K. pharmaceutical industry.

Access impact
The U.S.-U.K. trade deal will have significant implications for drug pricing and access in both countries. By exempting drugs from tariffs, the U.K. will be able to negotiate higher prices for new medicines, which could lead to increased access for patients. Additionally, the reduction of mandated rebates to England’s National Health Service could provide more financial stability for pharmaceutical companies and incentivize them to invest in research and development.

Top-3 domain lens
Cost-Effectiveness: The trade deal will see the U.K. relax cost-effectiveness rules for new drugs, potentially allowing for the approval of more medicines each year.
Evidence Quality & Robustness: The agreement includes commitments from both countries to strengthen their respective pharmaceutical industries and encourage investment.
Budget Impact & Resources: The reduction of mandated rebates to England’s National Health Service could provide more financial stability for pharmaceutical companies and encourage investment.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #U.S. #U.K. #PharmaceuticalIndustry #TradeDeal

CTA
Explore 350+ independent assessments: [https://mararating.com/mara-ratings-list](https://mararating.com/mara-ratings-list)

Source
source: https://www.biopharmadive.com/news/us-uk-drug-price-deal-pharmaceuticals-tariffs/806662/